Navigation Links
Decision Resources' Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals' Fostamatinib Disodium
Date:8/6/2009

WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, today released its updated Pharmacor Rheumatoid Arthritis report which now includes patient share and sales forecasts through 2018 for Rigel Pharmaceuticals' investigational novel oral agent, fostamatinib disodium (R788). The report update is based on Rigel Pharmaceuticals' recent announcement regarding additional Phase II clinical data for fostamatinib disodium.

The report finds that, owing to its impressive efficacy, the spleen tyrosine kinase (Syk) inhibitor fostamatinib disodium will likely precede TNF-alpha inhibitors such as Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's Humira in the treatment cascade for rheumatoid arthritis. Phase II data shows that fostamatinib disodium's efficacy is comparable to that of currently-available biologic agents in patients with inadequate response to treatment with methotrexate. According to the report, if the agent is priced lower than currently-available biologics, physicians may be willing to prescribe fostamatinib disodium as an alternative to premium-priced biologics.

However, Decision Resources conservatively forecasts that fostamatinib disodium's patient share will reach up to 1.8 percent and it will garner major-market sales of $330 million in 2018.

"Fostamatinib disodium's patient share and sales will be considerably lower than our evaluation of the other novel oral agent in development for rheumatoid arthritis--Pfizer's Jak-3 inhibitor CP-690550," said Decision Resources Analyst Joanna Kim, M.Ed. "Fostamatinib disodium's impact is likely to be less than that of CP-690550 because of uncertainties about its efficacy in the TNF-refractory population and the absence of a head-to-head trial against a TNF-alpha inhibitor."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                         Decision Resources, Inc.
    Christopher Comfort                        Elizabeth Marshall
    781-296-2597                               781-296-2563
    ccomfort@dresources.com                    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BCBSGA Announces Decision to Cover H1N1 Vaccine Administration
2. PET can help guide treatment decisions for a common pediatric cancer
3. WellPoint Announces Decision to Cover H1N1 Vaccine Administration
4. United States Patent Office Issues Decision in Re-examination Proceedings
5. Providence Service Corporation Comments on U.S. Court of Appeals Decision to Uphold Federal Injunction Blocking Californias 10% Cut in Medi-Cal Payments
6. Stem Cell Decision Opens New Doors, May Spur More Research
7. TriServ Likely to Protest Decision
8. Communicating science to decision makers
9. Brain section multitasks, handling phonetics and decision-making
10. The decision about the incision: Is midline or transverse better for abdominal surgery?
11. Jeff Stewart Joins Decision Resources, Inc. as Chief Information Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ePAY ... partnership with Connance, a healthcare industry leader providing predictive analytics to optimize ... combine to provide health systems, hospitals and ambulatory surgical centers with dramatic ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology: